



IBA to Showcase its Full Spectrum of Proton Therapy Solutions and Services at the American Society for Radiation Oncology (ASTRO) Conference

IBA's next generation single-room proton therapy system Proteus[®] ONE to be exhibited in a life-size model

Louvain-la-Neuve, Belgium – October 23, 2012 - IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, will be presenting its full spectrum of cutting edge proton therapy solutions, products and services at the American Society for Radiation Oncology (ASTRO) Conference from October 28-30, 2012 in Boston, MA, USA. IBA will be exhibiting a life size *Proteus[®] ONE*, IBA's next generation, single-room proton therapy solution at the Company's dedicated booth (#3019).

The *Proteus[®] ONE** system has been developed by IBA, the global leader in proton therapy with more than 55% market share, to allow more patients globally to access proton therapy. ProteusONE is a smaller, less expensive, faster to install proton therapy solution, without compromising the latest in proton therapy technology.

Olivier Legrain, Chief Executive Officer at IBA, commented: *"At IBA we believe that our Proton Therapy solutions are changing the way the world treats cancer. Proton therapy is a more precise and less damaging type of radiotherapy treatment with the same efficacy and improved outcomes for patients. Through our strong proton therapy offering and our compact, affordable single room solution in ProteusONE, IBA brings all the power of IBA Proteus systems within reach for more clinical centers worldwide. IBA's broad offering of proton therapy solutions and services is also reinforced by IBA's longstanding sector leading experience in the proton therapy field gained whilst treating more than twenty thousand patients globally."*

IBA will also be presenting the Company's recent advancements in its software solutions for proton therapy treatment delivery which will make it even easier for practitioners to manage, control and deliver proton therapy. Visitors will be able to create a proton therapy prescription and go through the workflow required to deliver the treatment on the latest proton therapy delivery software.



Moreover, IBA will be profiling its complete solutions for Proton Therapy Dosimetry, which are designed to minimize commissioning and QA times and to maximize patient throughput and safety. With IBA's technology, proton therapy centers will now be able to start treating patients faster, increase daily patient throughput and provide a higher patient treatment safety.

EVENT: Advancing Patient Care Through Innovation: The Role of Proton Therapy.

IBA will be hosting a reception after the symposium on October 29, organized by University of Florida Proton Therapy Institute entitled: *"Advancing Patient Care Through Innovation: The Role of Proton Therapy."*

The reception will start with an exclusive talk by Siddhartha Mukherjee, Pulitzer Prize Winner and Author of *"The Emperor of All Maladies: A Biography of Cancer"*.

**Proteus[®]ONE is the brand name of a new configuration of the Proteus[®]235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.*

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website: www.iba-protontherapy.com

Contact

IBA

William Hansen

Global Marketing Director

Tel: +1 612 804 55 59

William.Hansen@iba-group.com



For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer

+32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet

Vice-President Corporate Communication

+32 10 475 890

thomas.ralet@iba-group.com

For media and investor enquiries:

M:Communications

Mary-Jane Elliott, Amber Bielecka,
Claire Dickinson

+44 (0) 207 920 2333

IBA@mcomgroup.com